237 related articles for article (PubMed ID: 30266825)
1. Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase.
Muñoz IM; Morgan ME; Peltier J; Weiland F; Gregorczyk M; Brown FC; Macartney T; Toth R; Trost M; Rouse J
EMBO J; 2018 Dec; 37(24):. PubMed ID: 30266825
[TBL] [Abstract][Full Text] [Related]
2. Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
Baltussen LL; Negraes PD; Silvestre M; Claxton S; Moeskops M; Christodoulou E; Flynn HR; Snijders AP; Muotri AR; Ultanir SK
EMBO J; 2018 Dec; 37(24):. PubMed ID: 30266824
[TBL] [Abstract][Full Text] [Related]
3. A new consensus for evaluating CDKL5/STK9-dependent signalling mechanisms.
Eyers PA
EMBO J; 2018 Dec; 37(24):. PubMed ID: 30377159
[TBL] [Abstract][Full Text] [Related]
4. CDKL5 kinase controls transcription-coupled responses to DNA damage.
Khanam T; Muñoz I; Weiland F; Carroll T; Morgan M; Borsos BN; Pantazi V; Slean M; Novak M; Toth R; Appleton P; Pankotai T; Zhou H; Rouse J
EMBO J; 2021 Dec; 40(23):e108271. PubMed ID: 34605059
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Katayama S; Sueyoshi N; Inazu T; Kameshita I
Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Synaptic Bases of CDKL5 Disorder.
Zhu YC; Xiong ZQ
Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934
[TBL] [Abstract][Full Text] [Related]
8. Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
Barbiero I; De Rosa R; Kilstrup-Nielsen C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31438497
[TBL] [Abstract][Full Text] [Related]
9. Aminoglycoside drugs induce efficient read-through of
Fazzari M; Frasca A; Bifari F; Landsberger N
RNA Biol; 2019 Oct; 16(10):1414-1423. PubMed ID: 31232219
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Jhang CL; Lee HY; Chen JC; Liao W
Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
[TBL] [Abstract][Full Text] [Related]
11. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.
Trazzi S; De Franceschi M; Fuchs C; Bastianini S; Viggiano R; Lupori L; Mazziotti R; Medici G; Lo Martire V; Ren E; Rimondini R; Zoccoli G; Bartesaghi R; Pizzorusso T; Ciani E
Hum Mol Genet; 2018 May; 27(9):1572-1592. PubMed ID: 29474534
[TBL] [Abstract][Full Text] [Related]
12. In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Carli S; Chaabane L; Butti C; De Palma C; Aimar P; Salio C; Vignoli A; Giustetto M; Landsberger N; Frasca A
J Neurochem; 2021 May; 157(4):1253-1269. PubMed ID: 33448385
[TBL] [Abstract][Full Text] [Related]
13. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Valli E; Trazzi S; Fuchs C; Erriquez D; Bartesaghi R; Perini G; Ciani E
Biochim Biophys Acta; 2012; 1819(11-12):1173-85. PubMed ID: 22921766
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
[TBL] [Abstract][Full Text] [Related]
15. The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
Tramarin M; Rusconi L; Pizzamiglio L; Barbiero I; Peroni D; Scaramuzza L; Guilliams T; Cavalla D; Antonucci F; Kilstrup-Nielsen C
Hum Mol Genet; 2018 Jun; 27(12):2052-2063. PubMed ID: 29618004
[TBL] [Abstract][Full Text] [Related]
16. CDKL5 Deficiency Augments Inhibitory Input into the Dentate Gyrus That Can Be Reversed by Deep Brain Stimulation.
Hao S; Wang Q; Tang B; Wu Z; Yang T; Tang J
J Neurosci; 2021 Oct; 41(43):9031-9046. PubMed ID: 34544833
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
[TBL] [Abstract][Full Text] [Related]
18. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
[TBL] [Abstract][Full Text] [Related]
19. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
[TBL] [Abstract][Full Text] [Related]
20. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Trovò L; Fuchs C; De Rosa R; Barbiero I; Tramarin M; Ciani E; Rusconi L; Kilstrup-Nielsen C
Neurobiol Dis; 2020 May; 138():104791. PubMed ID: 32032735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
